Introduction: The aim of the study was to construct folic acid-modified PEGylated paramagnetic nanoparticles (MNPs) co-carrying tissue factor pathway inhibitor-2 (TFPI-2) and cisplatin (CDDP), and to study the molecular-targeting and inhibitory effects of the nanocomposite on non-small cell lung cancer (NSCLC) and liver cancer. Methods: Nanocomposites were prepared using amino-modified iron oxide nanoparticles as carriers, co-loading CDDP and PEGylated FA/TFPI-2. Transmission electron microscopy, UV absorption spectrum, and dynamic light scattering were employed to characterize the morphology, structure, particle size, and zeta potential of the nanocomposite. The phenylenediamine method was used to detect the loading of CDDP, and the CCK-8 assay was used to detect the toxic effect of the nanocomposite on HUVECs, A549, and NCI-H460 cells. In tumor-bearing mice models, the antitumor effects of the nanocomposites were assessed using TUNEL staining (at the molecular level), reverse transcriptase quantitative polymerase chain reaction (at the gene level), hematoxylin and eosin staining (at the cellular level), and the appearance of the mice models. Results: The synthesized FA-MNP/CDDP/TFPI-2 nanocomposite was uniformly dispersed and spherical in shape (approximate diameter: 10 nm). The zeta potential of particles was −9.44 mV, and the average particle size was 25 nm. The loading amount of CDDP was 70.24 μg/mL (23.33%). The nanocomposite was nontoxic to HUVECs, while it showed a favorable inhibitory effect on A549 and NCI-H460 cells. In vivo experiments in mice demonstrated satisfactory imaging properties and therapeutic effects of nanocomposite against liver cancer. Discussion: FA-MNP/CDDP/TFPI-2 may provide insights for the development of new chemotherapeutic drugs.

Keywords:
Cisplatin, Tissue factor pathway inhibitor-2, Nanocarrier, Folic acid, Liver cancer, Non-small cell lung cancer
1.
He Z, Shi Z, Sun W, Ma J, Xia J, Zhang X, et al. Hemocompatibility of folic-acid-conjugated amphiphilic PEG-PLGA copolymer nanoparticles for co-delivery of cisplatin and paclitaxel: treatment effects for non-small-cell lung cancer. Tumor Biol. 2016;37(6):7809–21.
2.
Toffart AC, Duruisseaux M, Brichon PY, Pirvu A, Villa J, Selek L, et al. Operation and chemotherapy: prognostic factors for lung cancer with one synchronous metastasis. Ann Thorac Surg. 2018;105(3):957–65.
3.
Peng Y, Ren W, Wang H, Li M, Feng Z, Peng Z. Surgical treatment is an effective approach for patients with synchronous multiple primary lung cancers. J Cancer Res Ther. 2017;13(4):702–6.
4.
Gravara LD, Battiloro C, Cantile R, Letizia A, Vitiello F, Montesarchio V, et al. Chemotherapy and/or immune checkpoint inhibitors in NSCLC first-line setting what is the best approach? Lung Cancer Manag. 2020;9(1):LMT22.
5.
Garcia-Chias B, Figuero E, Castelo-Fernandez B, Cebrian-Carretero JL, Cerero-Lapiedra R. Prevalence of oral side effects of chemotherapy and its relationship with periodontal risk: a cross sectional study. Support Care Cancer. 2019;27(9):3479–90.
6.
Grimaldi A, Cammarata I, Martire C, Focaccetti C, Piconese S, Buccilli M, et al. Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigens. Commun Biol. 2020;3(1):85.
7.
Hong Y, Che S, Hui B, Wang X, Zhang X, Ma H. Combination therapy of lung cancer using layer-by-layer cisplatin prodrug and curcumin co-encapsulated nanomedicine. Drug Des Devel Ther. 2020;14:2263–74.
8.
Zhang D, Hedlund EME, Lim S, Chen F, Zhang Y, Sun B, et al. Antiangiogenic agents significantly improve survival in tumor-bearing mice by increasing tolerance to chemotherapy-induced toxicity. Proc Natl Acad Sci U S A. 2011;108(10):4117–22.
9.
Liu B, Han L, Liu J, Han S, Chen Z, Jiang L. Co-delivery of paclitaxel and TOS-cisplatin via TAT-targeted solid lipid nanoparticles with synergistic antitumor activity against cervical cancer. Int J Nanomedicine. 2017;12:955–68.
10.
Katsurada N, Tachihara M, Hatakeyama Y, Koyama K, Yumura M, Kiriu T, et al. Feasibility study of adjuvant chemotherapy with carboplatin and nab-paclitaxel for completely resected NSCLC. Cancer Manag Res. 2020;12:777–82.
11.
Yang Y, Zhang C, Li S, Liu J, Qin Y, Ge A. Tissue factor pathway inhibitor 2 suppresses the growth of thyroid cancer cells through by induction of apoptosis. Asia Pac J Clin Oncol. 2021;17:e48–56.
12.
Yanamandra N, Kondraganti S, Gondi CS, Gujrati M, Olivero WC, Dinh DH, et al. Recombinant adeno-associated virus (rAAV) expressing TFPI-2 inhibits invasion, angiogenesis and tumor growth in a human glioblastoma cell line. Int J Cancer. 2005;115(6):998–1005.
13.
Gessler F, Voss V, Seifert V, Gerlach R, Kögel D. Knockdown of TFPI-2 promotes migration and invasion of glioma cells. Neurosci Lett. 2011;497(1):49–54.
14.
George J, Gondi CS, Dinh DH, Gujrati M, Rao JS. Restoration of tissue factor pathway inhibitor-2 in a human glioblastoma cell line triggers caspase-mediated pathway and apoptosis. Clin Cancer Res. 2007;13(12):3507–17.
15.
Kwon YM, Je JY, Cha SH, Oh Y, Cho WH. Synergistic combination of chemophototherapy based on temozolomide/ICGloaded iron oxide nanoparticles for brain cancer treatment. Oncol Rep. 2019;42(5):1709–24.
16.
Gong T, Dong Z, Fu Y, Gong T, Deng L, Zhang Z. Hyaluronic acid modified doxorubicin loaded Fe3O4 nanoparticles effectively inhibit breast cancer metastasis. J Mater Chem B. 2019;7(38):5861–72.
17.
Shen JM, Li XX, Fan LL, Zhou X, Han JM, Jia MK, et al. Heterogeneous dimer peptide-conjugated polylysine dendrimer-Fe3O4 composite as a novel nanoscale molecular probe for early diagnosis and therapy in hepatocellular carcinoma. Int J Nanomedicine. 2017;12:1183–200.
18.
Sanchez-Cabezas S, Montes-Robles R, Gallo J, Sancenon F, Martinez-Manez R. Combining magnetic hyperthermia and dual T1/T2 MR imaging using highly versatile iron oxide nanoparticles. Dalton Trans. 2019;48(12):3883–92.
19.
Park YI, Kwon SH, Lee G, Motoyama K, Kim MW, Lin M, et al. pH-sensitive multi-drug liposomes targeting folate receptor beta for efficient treatment of non-small cell lung cancer. J Control Release. 2021;330:1–14.
20.
Moazzen S, Dolatkhah R, Tabrizi JS, Shaarbafi J, Alizadeh BZ, de Bock GH, et al. Folic acid intake and folate status and colorectal cancer risk: a systematic review and meta-analysis. Clin Nutr. 2018;37(6):1926–34.
21.
Wang X, Tu M, Tian B, Yi Y, Wei Z, Wei F. Synthesis of tumor-targeted folate conjugated fluorescent magnetic albumin nanoparticles for enhanced intracellular dual-modal imaging into human brain tumor cells. Anal Biochem. 2016;512:8–17.
22.
Li W, Xue B, Shi K, Qu Y, Chu B, Qian Z. Magnetic iron oxide nanoparticles/10-hydroxy camptothecin co-loaded nanogel for enhanced photothermal-chemo therapy. Appl Mater Today. 2019;14:84–95.
23.
Boddolla S, Thodeti S. A review on characterization techniques of nanomaterials. Int J Eng Sci Math. 2018;7(1):169–75.
24.
Mourdikoudis S, Pallares RM, Thanh NTK. Characterization techniques for nanoparticles: comparison and complementarity upon studying nanoparticle properties. Nanoscale. 2018;10(27):12871–934.
25.
MacCuspie RI. Chapter 4: characterization of nanomaterials for nanoEHS studies. 3rd ed. In: Hull MS, Bowman DM, editors. Nanotechnology environmental health and safety. Boston, MA: William Andrew Publishing; 2018. p. 59–82.
26.
Zaidi Y, Arjmand F, Zaidi N, Usmani JA, Zubair H, Akhtar K, et al. A comprehensive biological insight of trinuclear copper(II)-tin(IV) chemotherapeutic anticancer drug entity: in vitro cytotoxicity and in vivo systemic toxicity studies. Metallomics. 2014;6(8):1469–79.
27.
Riviere K, Huang Z, Jerger K, Macaraeg N, Szoka FC Jr. Antitumor effect of folate-targeted liposomal doxorubicin in KB tumor-bearing mice after intravenous administration. J Drug Target. 2011;19(1):14–24.
28.
Santra S, Kaittanis C, Grimm J, Perez JM. Drug/dye-loaded, multifunctional iron oxide nanoparticles for combined targeted cancer therapy and dual optical/magnetic resonance imaging. Small. 2009;5(16):1862–8.
29.
Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol. 2010;7(11):653–64.
30.
Hull LC, Farrell D, Grodzinski P. Highlights of recent developments and trends in cancer nanotechnology research: view from NCI Alliance for Nanotechnology in Cancer. Biotechnol Adv. 2014;32(4):666–78.
31.
Dhaliwal A, Zheng G. Improving accessibility of EPR-insensitive tumor phenotypes using EPR-adaptive strategies: designing a new perspective in nanomedicine delivery. Theranostics. 2019;9(26):8091–108.
32.
Kosmides AK, Sidhom J-W, Fraser A, Bessell CA, Schneck JP. Dual targeting nanoparticle stimulates the immune system to inhibit tumor growth. ACS Nano. 2017;11(6):5417–29.
33.
Dong Z, Guo J, Xing X, Zhang X, Du Y, Lu Q. RGD modified and PEGylated lipid nanoparticles loaded with puerarin: formulation, characterization and protective effects on acute myocardial ischemia model. Biomed Pharmacother. 2017;89:297–304.
34.
Ge S, Zhang Q, Wang X, Shao Q, Bao L, Ding R, et al. Bacteria-directed construction of ZnO/CdS hollow rods and their enhanced photocatalytic activity. J Nanosci Nanotechnol. 2016;16(5):4929–35.
35.
Liu P, Zhao Y, Qin R, Mo S, Chen G, Gu L, et al. Photochemical route for synthesizing atomically dispersed palladium catalysts. Science. 2016;352(6287):797–800.
36.
Yuan Y, Ding Z, Qian J, Zhang J, Xu J, Dong X, et al. Casp3/7-instructed intracellular aggregation of Fe3O4 nanoparticles enhances T2 MR imaging of tumor apoptosis. Nano Lett. 2016;16(4):2686–91.
37.
He Z, Huang J, Xu Y, Zhang X, Teng Y, Huang C, et al. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer. Oncotarget. 2015;6(39):42150–68.
38.
Tan S, Wang G. Lung cancer targeted therapy: folate and transferrin dual targeted, glutathione responsive nanocarriers for the delivery of cisplatin. Biomed Pharmacother. 2018;102:55–63.
39.
Andrade RJ, Chalasani N, Björnsson ES, Suzuki A, Kullak-Ublick GA, Watkins PB, et al. Drug-induced liver injury. Nat Rev Dis Primers. 2019;5(1):58.
40.
Zhou F, Teng F, Deng P, Meng N, Song Z, Feng R. Recent progress of nano-drug delivery system for liver cancer treatment. Anticancer Agents Med Chem. 2018;17(14):1884–97.
41.
Lin G, Cortez-Jugo C, Ju Y, Besford QA, Ryan TM, Pan S. Microemulsion-assisted templating of metal-stabilized poly(ethylene glycol) nanoparticles. Biomacromolecules. 2020;22(2):612–9.
42.
Bendtsen KM, Gren L, Malmborg VB, Shukla PC, Tuner M, Essig YJ, et al. Particle characterization and toxicity in C57BL/6 mice following instillation of five different diesel exhaust particles designed to differ in physicochemical properties. Part Fibre Toxicol. 2020;17(1):38.
43.
Zhou Y, Dai Z. New strategies in the design of nanomedicines to oppose uptake by the mononuclear phagocyte system and enhance cancer therapeutic efficacy. Chem Asian J. 2018;13(22):3333–40.
44.
Bakrania A, Zheng G, Bhat M. Nanomedicine in hepatocellular carcinoma: a new frontier in targeted cancer treatment. Pharmaceutics. 2021;14(1):41.
45.
Zhang Z, Zhang J, Tian J, Li H. A polydopamine nanomedicine used in photothermal therapy for liver cancer knocks down the anti-cancer target NEDD8-E3 ligase ROC1 (RBX1). J Nanobiotechnology. 2021;19(1):323.
46.
Zhang R, Wang L, Wang X, Jia Q, Chen Z, Yang Z, et al. Acid-induced in vivo assembly of gold nanoparticles for enhanced photoacoustic imaging-guided photothermal therapy of tumors. Adv Healthc Mater. 2020;9(14):e2000394.
47.
Lee YT, Tan YJ, Oon CE. Molecular targeted therapy: treating cancer with specificity. Eur J Pharmacol. 2018;834:188–96.
48.
Du Y, Chen B. Combination of drugs and carriers in drug delivery technology and its development. Drug Des Devel Ther. 2019;13:1401–8.
49.
Villaverde G, Baeza A. Targeting strategies for improving the efficacy of nanomedicine in oncology. Beilstein J Nanotechnol. 2019;10:168–81.
50.
Khan AU. Nanodrugs: optimism for emerging trend of multidrug resistance. Int J Nanomedicine. 2012;7:4323–4.
51.
Kemp JA, Kwon YJ. Cancer nanotechnology: current status and perspectives. Nano Converg. 2021;8(1):34.
52.
Anchordoquy TJ, Barenholz Y, Boraschi D, Chorny M, Decuzzi P, Dobrovolskaia MA, et al. Mechanisms and barriers in cancer nanomedicine: addressing challenges, looking for solutions. ACS Nano. 2017;11(1):12–8.
53.
Dunuweera SP, Rajapakse RMSI, Rajapakshe RBSD, Wijekoon SHDP, Nirodha Thilakarathna MGGS, Rajapakse RMG. Review on targeted drug delivery carriers used in nanobiomedical applications. Curr Nanosci. 2019;15(4):382–97.
© 2022 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2022
You do not currently have access to this content.